Back
| autoid | 19 |
| crg_id | CRG080500008 |
| titleoftrial | Effect of Lipid lowering therapy On the progression of Renal Disease |
| acronymnoftrial | LORD Trial |
| website | http:// |
| identificationno | H6723; ACTRN12605000693628 |
| leadprefix | A/Prof |
| leadsurname | Fassett |
| leadgivennames | Rob |
| leadposition | Director of Medicine, Director of Renal Unit |
| leaddepartment | Renal Research Tasmania |
| leadorganisation | Launceston General Hospital |
| leadaddress | Level 5, LGH, Charles Street, Launceston, Tasmania, Australia |
| leademail | rob.fassett@dhhs.tas.gov.au |
| leadphone | +61 3 63487190 |
| leadfax | +61 3 63 487577 |
| leadsuffix | |
| contactprefix | Mrs |
| contactsurname | Purse & Smith |
| contactgivennames | Lisa & Marianne |
| contactposition | Study Co-ordiantors |
| contactdepartment | Renal Research Tasmania |
| contactorganisation | Launceston General Hospital |
| contactaddress | Level Five, Charles Street , Launceston |
| contactemail | lisa.purse@dhhs.tas.gov.au; marianne.smith@dhhs.tas.gov.au |
| contactphone | +61 3 63 48 7026 |
| contactfax | +61 3 63 48 7026 |
| funding | |
| otherfunding | Charity for Medical Research |
| fundingnameofsponsors | Clifford Craig Medical Research Trust |
| ethicsapproval | yes |
| studytype | randomised |
| studytype_other | |
| groupassignment | parallel |
| blinding_patients | yes |
| blinding_investigators | yes |
| blinding_outcomes | yes |
| blinding_analysts | yes |
| proposedstart | 3/ 2001 |
| actualstart | 2/ 2002 |
| proposedcompletiondate | 2005 |
| actualcompletiondate | 2008 |
| multi_center_study | no |
| numberofcentres | |
| multi_national_study | no |
| countrycentres | Australia |
| researchquestion | To determine the effect of an HMG-CoA reductase inhibitor on the progression of renal disease |
| study_status_recruitment | no_longer_recruiting |
| study_status_recruitment_follow | ongoing |
| healthcarecondition | Chronic Kidney Disease |
| intervention1 | Atorvastatin / Placebo |
| intervention2 | |
| intervention3 | |
| intervention4 | |
| participants_gender | both |
| participants_other | adults |
| age | Min. 18 and Max 85 |
| totalrecruitment | 200 |
| inclusion | Age >18 years and < 85 years History of Chronic Kidney Disease Serum Creat >130umol/L male and >120 umol/L female Creat Clearance < 60ml/min |
| exclusion | Already taking a statin Medical Conditions likely to affect response to Atorvastatin Concurrent Meds likely to affect response of Atorvastatin Hypersensitivity to atorvastatin Participation or proposed participation in another clinical investigational drug study within 30 days |
| primaryoutcomes | To determine change in renal function measured by eGFR |
| secondaryoutcomes | Assess effects of Atorvastatin therapy on need for renal replacement therapy mortality and cause of death Quality of life Functional Status Number of hospital admissions number of cardiovascular events nutritional status safety of long term administration of atorvastatin to normalise lipid levels |
| reference | 1.K. Oliver, M. J. Summers, R. G. Fassett and J. S. Coombes. Cognitive Function in LORD Study Patients. Launceston General Hospital Medical Research Week 2005 2.R.G. Fassett, J. E. Sharman, M. Smith, L. Anderson, J.S. Coombes. Serum potassium is significantly associated with increased arterial stiffness in patients with chronic kidney disease. World Congress of Nephrology, Singapore, 2005.Nephrology, 10: A104,2005. 3.R.G. Fassett, J.S. Coombes, L. Purse, M. Smith, K. Chugg, D.P. Geraghty and M. J. Ball. Dietary intake of patients with chronic kidney disease. Hong Kong Journal of Nephrology, 6: 1, A4, 2004. 4.J.S. Coombes, R.G. Fassett, L. Purse, M. Smith, K. Chugg and D.P. Geraghty. Physical Activity, self reported health and quality of life in patients with chronic renal impairment. Journal of The American Society of Nephrology, 14: 448A, 2003. 5.R.G. Fassett, J.S. Coombes, L. Purse, M. Smith and K. Chugg. No relationship between lipid levels and renal function in patients with chronic renal impairment. Journal of The American Society of Nephrology, 14: 530A, 2003. 6.R.G. Fassett, J.S. Coombes, L. Purse, M. Smith, K. Chugg and D.P. Geraghty. Enrollment in a clinical trial improves renal function. Journal of The American Society of Nephrology, 14: 768A, 2003. 7.J.S. Coombes, R.G. Fassett, L. Purse, M. Smith, K. Chugg, D.P. Geraghty and M. J. Ball. Dietary intake of patients with chronic renal impairment. Journal of The American Society of Nephrology, 14: 791A, 2003. |